Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Future Microbiol ; 13: 785-798, 2018 06 01.
Article in English | MEDLINE | ID: mdl-29848058

ABSTRACT

AIM: Investigate the role of hypoxia-inducible factor-1α (HIF-1α) in pulmonary tuberculosis (TB). METHODS & RESULTS: A model of progressive pulmonary TB in BALB/c mice, immunohistochemistry and digital pathology were used. High HIF-1α expression was observed during early TB in activated macrophages. During late TB, even higher HIF-1α expression was observed in foamy macrophages, which are resistant to apoptosis. Blocking HIF-1α during early infection with 2-methoxyestradiol worsened the disease, while during late TB, it induced macrophage apoptosis and decreased bacillary loads. CONCLUSION: HIF-1α has a dual role in experimental TB. This finding could have therapeutic implications because combined treatment with 2-methoxyestradiol and antibiotics appeared to eliminate mycobacteria more efficiently than conventional chemotherapy during advanced disease.


Subject(s)
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Tuberculosis, Pulmonary/metabolism , 2-Methoxyestradiol/administration & dosage , Animals , Antitubercular Agents/administration & dosage , Apoptosis/drug effects , Disease Models, Animal , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Macrophages/cytology , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/genetics , Tuberculosis, Pulmonary/physiopathology
2.
Leuk Lymphoma ; 59(11): 2628-2638, 2018 11.
Article in English | MEDLINE | ID: mdl-29616858

ABSTRACT

Resistance to chemotherapy hinders the successful treatment of acute lymphoblastic leukemia (ALL). The multi-drug resistance-1 (MDR1/ABCB1) gene encodes P-glycoprotein (P-gp), which plays an important role in chemoresistance; however, its transcriptional regulation remains unclear. We investigated the role of YY1 in the regulation of MDR1 and its relation to ALL outcomes. Analysis of the MDR1 promoter revealed four putative YY1-binding sites, which we analyzed using a reporter system and ChIP analysis. YY1 silencing resulted in the inhibition of MDR1 expression and function. The clinical roles of YY1 and MDR1 expression were evaluated in children with ALL. Expression of both proteins was increased in ALL patients compared to controls. We identified a positive correlation between YY1 and MDR1 expression. High levels of YY1 were associated with decreased overall survival. Our results demonstrated that YY1 regulates the transcription of MDR1. Therefore, YY1 may serve as a useful prognostic and/or therapeutic target.


Subject(s)
Biomarkers, Tumor/analysis , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Gene Expression Regulation, Neoplastic , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , YY1 Transcription Factor/metabolism , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B/metabolism , Adolescent , Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis , Cell Proliferation , Child , Child, Preschool , Cohort Studies , Etoposide/pharmacology , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prognosis , Promoter Regions, Genetic , Survival Rate , Tumor Cells, Cultured , YY1 Transcription Factor/genetics
3.
Tuberculosis (Edinb) ; 96: 87-95, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26786659

ABSTRACT

Mycobacterium tuberculosis (M. tb) is the etiological agent of pulmonary tuberculosis (TB); this disease remains a worldwide health problem. Yin-Yang-1 (YY1) plays a major role in the maintenance and progression of some pulmonary diseases, including pulmonary fibrosis. However, the role of YY1 in TB remains unknown. The aim of this study was to elucidate the role of YY1 in the regulation of CCL4 and its implication in TB. We determined whether YY1 regulates CCL4 using reporter plasmids, ChIP and siRNA assays. Immunohistochemistry and digital pathology were used to measure the expression of YY1 and CCL4 in a mouse model of TB. A retrospective comparison of patients with TB and control subjects was used to measure the expression of YY1 and CCL4 using tissue microarrays. Our results showed that YY1 regulates the transcription of CCL4; moreover, YY1, CCL4 and TGF-ß were overexpressed in the lung tissues of mice with TB during the late stages of the disease and the tissues of TB patients. The expression of CCL4 and TGF-ß correlated with YY1 expression. In conclusion, YY1 regulates CCL4 transcription; moreover, YY1 is overexpressed in experimental and human TB and is positively correlated with CCL4 and TGF-ß expression. Therefore, treatments that decrease YY1 expression may be a new therapeutic strategy against TB.


Subject(s)
Chemokine CCL4/metabolism , Lung/microbiology , Tuberculosis, Pulmonary/metabolism , YY1 Transcription Factor/metabolism , Animals , Cell Line , Chemokine CCL4/genetics , Chromatin Immunoprecipitation , Disease Models, Animal , Disease Progression , Gene Expression Regulation , Host-Pathogen Interactions , Humans , Immunohistochemistry , Lung/immunology , Male , Mice, Inbred BALB C , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/pathogenicity , RNA Interference , Retrospective Studies , Signal Transduction , Time Factors , Tissue Array Analysis , Transcription, Genetic , Transfection , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolism , Tuberculosis, Pulmonary/genetics , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/microbiology , YY1 Transcription Factor/genetics
4.
Kidney Int ; 89(2): 363-73, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26509589

ABSTRACT

Despite clinical recovery of patients from an episode of acute kidney injury (AKI), progression to chronic kidney disease (CKD) is possible on long-term follow-up. However, mechanisms of this are poorly understood. Here, we determine whether activation of angiotensin-II type 1 receptors during AKI triggers maladaptive mechanisms that lead to CKD. Nine months after AKI, male Wistar rats develop CKD characterized by renal dysfunction, proteinuria, renal hypertrophy, glomerulosclerosis, tubular atrophy, and tubulointerstitial fibrosis. Renal injury was associated with increased oxidative stress, inflammation, α-smooth muscle actin expression, and activation of transforming growth factor ß; the latter mainly found in epithelial cells. Although administration of losartan prior to the initial ischemic insult did not prevent or reduce AKI severity, it effectively prevented eventual CKD. Three days after AKI, renal dysfunction, tubular structural injury, and elevation of urinary biomarkers were present. While the losartan group had similar early renal injury, renal perfusion was completely restored as early as day 3 postischemia. Further, there was increased vascular endothelial growth factor expression and an early activation of hypoxia-inducible factor 1 α, a transcription factor that regulates expression of many genes that help reduce renal injury. Thus, AT1 receptor antagonism prior to ischemia prevented AKI to CKD transition by improving early renal blood flow recovery, lesser inflammation, and increased hypoxia-inducible factor 1 α activity.


Subject(s)
Acute Kidney Injury/complications , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Losartan/therapeutic use , Renal Insufficiency, Chronic/prevention & control , Reperfusion Injury/complications , Acute Kidney Injury/prevention & control , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Drug Evaluation, Preclinical , Kidney/blood supply , Kidney/drug effects , Losartan/pharmacology , Male , Rats, Wistar , Renal Insufficiency, Chronic/etiology , Reperfusion Injury/prevention & control
5.
Arch Virol ; 159(2): 291-305, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23990055

ABSTRACT

HPV L1-based virus-like particles vaccines (VLPs) efficiently induce temporary prophylactic activity through the induction of neutralizing antibodies; however, VLPs that can provide prophylactic as well as therapeutic properties for longer periods of time are needed. For this purpose, we generated a novel HPV 16 L1-based chimeric virus-like particle (cVLP) produced in plants that contains a string of T-cell epitopes from HPV 16 E6 and E7 fused to its C-terminus. In the present study, we analyzed the persistence of specific IgG antibodies with neutralizing activity induced by immunization with these cVLPs, as well as their therapeutic potential in a tumor model of C57BL/6 mice. We observed that these cVLPs induced persistent IgG antibodies for over 12 months, with reactivity and neutralizing activity for VLPs composed of only the HPV-16 L1 protein. Efficient protection for long periods of time and inhibition of tumor growth induced by TC-1 tumor cells expressing HPV-16 E6/E7 oncoproteins, as well as significant tumor reduction (57 %), were observed in mice immunized with these cVLPs. Finally, we discuss the possibility that chimeric particles of the type described in this work may be the basis for developing HPV prophylactic and therapeutic vaccines with high efficacy.


Subject(s)
Capsid Proteins/immunology , Carcinoma/prevention & control , Oncogene Proteins, Viral/immunology , Papillomavirus E7 Proteins/immunology , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/immunology , Repressor Proteins/immunology , Vaccines, Virus-Like Particle/immunology , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Capsid Proteins/genetics , Carcinoma/immunology , Carcinoma/therapy , Disease Models, Animal , Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/immunology , Female , Mice , Mice, Inbred C57BL , Oncogene Proteins, Viral/genetics , Papillomavirus E7 Proteins/genetics , Papillomavirus Infections/complications , Papillomavirus Infections/immunology , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Repressor Proteins/genetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Virus-Like Particle/administration & dosage , Vaccines, Virus-Like Particle/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...